Retinal abnormalities in β-thalassemia major.
Devang L Bhoiwala1, Joshua L Dunaief2
1Department of Ophthalmology, F. M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, Philadelphia, Pennsylvania, USA; Department of Ophthalmology, Albany Medical College, Albany, New York, USA.
Survey of Ophthalmology
|September 2, 2015
Summary
Beta-thalassemia (β-thalassemia) patients experience ocular complications due to iron overload or chelation therapy. This study examines retinal abnormalities and iron toxicity mechanisms in beta-thalassemia major.
Area of Science:
- Ophthalmology
- Hematology
- Genetics
Background:
- Beta-thalassemia (β-thalassemia) patients suffer multi-organ complications, including significant ocular issues.
- Ocular manifestations range from visual acuity deficits to acute vision loss.
Purpose of the Study:
- To investigate retinal abnormalities in beta-thalassemia major (β-thalassemia major).
- To explore the role of retinal iron toxicity in the pathogenesis of these ocular complications.
Main Methods:
- Review of existing literature on ocular findings in β-thalassemia.
- Analysis of mechanisms underlying retinal iron accumulation and toxicity.
Main Results:
- Retinal degeneration in β-thalassemia major can stem from iron overload or iron chelation therapy side effects.
- Both transfusion-dependent and non-chelated patients exhibit retinopathy, suggesting complex iron-related mechanisms.
Conclusions:
- Retinal abnormalities are a critical concern in β-thalassemia management.
- Understanding iron toxicity mechanisms is vital for preventing vision loss in these patients.
